This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Telintra (IV)

MabVax Therapeutics Holdings, Inc.

Drug Names(s): TLK199 intravenous, ezatiostat hydrochloride liposomes

Description: BioMedTracker has a separate Drug Profile for the oral formulation of ezatiostat HCl. Please also see Telintra (Oral).

Telintra is a small molecule product candidate designed to stimulate the production of blood cells in the bone marrow. Telintra utilizes Telik's TRAP (Target-Related Affinity Profiling) technology. Telintra inhibits the enzymatic activity of glutathione S-transferase P1-1 (GST P1-1), an enzyme which displays antiapoptotic activity and is also involved in the cellular resistance to anticancer drugs. Inhibition of this enzyme, in animals, augments white blood cell production.

Deal Structure: Telik and MabVax
In May 2014, Telik and MabVax have entered into a definitive merger agreement. Under the terms of the merger agreement, MabVax will merge with a wholly-owned subsidiary of Telik in an all-stock transaction.

Telintra (IV) News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug